Summary & Overview
HCPCS Level II J7685: Tobramycin Inhalation Solution, Compounded, 300 mg
HCPCS Level II code J7685 identifies a compounded inhalation formulation of tobramycin supplied in unit-dose 300 mg vials for use with durable medical equipment (DME). This code matters nationally because inhaled antibiotics are a key therapy for chronic respiratory infections in select patient populations, and compounded products introduce specific coverage, sourcing, and billing considerations for payers and providers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for inhaled tobramycin, the service setting implications for home and outpatient care, and typical billing considerations tied to compounded inhalation products administered via DME.
The publication outlines what to expect from benchmarks and coverage patterns, highlights policy-relevant points such as compounded product classification and DME-associated service lines, and summarizes common modifier usage where applicable. Data not provided in the input (including associated taxonomies, ICD-10 diagnoses, and related codes) is noted as unavailable. The goal is to give payers, billing staff, and health policy stakeholders a clear, national-level briefing on the operational and coding aspects of J7685.
Billing Code Overview
HCPCS Level II code J7685 describes Tobramycin, inhalation solution, compounded product, administered through DME, unit dose form, per 300 milligrams. The service represented by this code is a compounded inhalation antibiotic preparation of tobramycin supplied in unit-dose form and intended for administration using durable medical equipment (DME) designed for inhalation therapy.
Service type: Compounded inhalation medication administration via DME
Typical site of service: Home or outpatient settings where durable medical equipment for inhalation is used, including patient residences and outpatient infusion or respiratory therapy clinics.
Clinical & Coding Specifications
Clinical Context
A 10-year-old patient with cystic fibrosis and chronic Pseudomonas aeruginosa airway colonization presents for home respiratory therapy. The pulmonologist prescribes inhaled tobramycin inhalation solution in unit dose 300 mg vials to be compounded and supplied through the durable medical equipment (DME) supplier for administration via a nebulizer. The care workflow includes: the physician documents indication and dosing in the chart; a prescription is sent to the pharmacy or DME that compounds sterile unit-dose vials; the DME supplies the inhalation solution and nebulizer; respiratory therapists train the patient/caregiver on reconstitution (if applicable), dosing schedule (typically 28 days on, 28 days off), inhalation technique, device maintenance, and adverse effect monitoring; periodic clinic follow-up includes audiology screening and renal function monitoring because of potential ototoxicity and nephrotoxicity. Billing uses HCPCS code J7685 for each 300 mg unit dose administered or dispensed through DME. Patient education, medication reconciliation, and documentation of inhalation sessions are part of the clinical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When unusual effort or time is required for patient education or training related to medication administration beyond usual practice |